$33.230
-0.847 (-2.55%)Al cierre
Noticias de GMAB
Eventos de GMAB
Genmab Reports Q2 Net Profit of $303M
Reports Q2 net profit $303M vs. $336M last year. "The second quarter of 2026 delivered clinical progress for our late-stage portfolio. Epcoritamab continued to demonstrate its potential as a core therapy across the spectrum of B-cell malignancies, with strong data across multiple treatment settings and patient populations. At the same time, new data further support the development of Rina-S in combination in advanced ovarian cancer. Together, these results reflect our continued commitment to delivering meaningful advances for patients," said Jan van de Winkel, Ph.D., Chief Executive Officer of Genmab.
Genmab Narrows FY26 Adjusted Operating Profit View to $1.065B-$1.385B
Narrows FY26 adjusted operating profit view to $1.065B-$1.385B from $900M-$1.4B. "Genmab is updating its revenue, adjusted operating expenses and adjusted operating profit guidance for 2026. The improved guidance is driven by higher total royalty revenues from DARZALEX and net sales of EPKINLY," the company stated.
Genmab Reports DARZALEX Q2 Sales of $4.207B
Genmab (GMAB) announced that worldwide net trade sales of DARZALEX, or daratumumab, including sales of the subcutaneous, or SC, product, daratumumab and hyaluronidase-fihj, sold under the tradename DARZALEX FASPRO in the U.S., as reported by J&J (JNJ) were $4.207B in the Q2. Net trade sales were $2.435B in the U.S. and $1.772B in the rest of the world. Genmab receives royalties on the worldwide net sales of DARZALEX, both the intravenous and SC products, under the exclusive worldwide license to J&J to develop, manufacture and commercialize daratumumab.
Genmab Receives Approval for TEPKINLY in Combination Therapy for Relapsed Follicular Lymphoma
Genmab (GMAB) announced that the European Commission granted marketing authorization for TEPKINLY in combination with lenalidomide and rituximab for the treatment of adult patients with relapsed or refractory follicular lymphoma. The approval is based on results from the pivotal Phase 3 EPCORE FL-1 trial that evaluated fixed-duration TEPKINLY + R2 compared to standard of care R2. "Follicular lymphoma is a persistent form of cancer that remains incurable, which means patients need more treatment options. Patients often relapse and experience shorter remissions and have fewer treatment options each time the disease returns," said Catherine Thieblemont, M.D., Ph.D., head of the hemato-oncology department, Paris Cite University, Hopital Saint-Louis Assistance-Publique-Hopitaux de Paris (APHP) in Paris. "The results shown in the EPCORE FL-1 trial are clinically meaningful, demonstrating the potential for TEPKINLY + R2 to change the treatment paradigm for patients, offering the chance at a durable response with a chemotherapy-free option." Epcoritamab is being co-developed by Genmab and AbbVie (ABBV) as part of the companies' oncology collaboration. The companies share commercial responsibilities in the U.S. and Japan, with AbbVie responsible for further global commercialization.
Genmab Reports Significant Results from EPCORE DLBCL-4 Trial
Genmab (GMAB) announced topline results from the Phase 3 EPCORE DLBCL-4 trial evaluating the combination of fixed duration epcoritamab, a T-cell engaging bispecific antibody administered subcutaneously, and lenalidomide, compared to standard-of-care, rituximab plus gemcitabine plus oxaliplatin, in adult patients with relapsed or refractory diffuse large B-cell lymphoma who received at least one prior line of treatment. Based on topline results, the trial met its primary objective, demonstrating statistically significant and clinically meaningful improvement in progression-free survival. The risk of disease progression and death was reduced by 60% and 56%, based on different censoring rules in the U.S. and outside the U.S., respectively. The safety profile of epcoritamab when administered in combination with lenalidomide was consistent with the previously reported safety profiles of the individual agents. "These topline results add to the growing evidence supporting the versatility of epcoritamab-based combinations, including fixed-duration epcoritamab, across lines of therapy for patients with relapsed or refractory large B-cell lymphoma who received at least one prior treatment," said Jan van de Winkel, CEO of Genmab. "With each new combination and treatment setting, we are building on our vision for epcoritamab as a core therapy across B-cell malignancies. We look forward to engaging with regulatory authorities as we continue to advance this program." Genmab and AbbVie (ABBV) will engage global regulatory authorities. Data will be submitted for presentation at a future medical meeting.
Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.